Medical imaging software and devices company Exo has launched SweepAI, an AI-driven cardiac and lung scanning ultrasound application.

Approved by the US Food and Drug Administration (FDA), SweepAI integrates intelligent scanning capabilities into the Exo Iris ultrasound system.

This advanced AI technology provides instant feedback during organ scans, automatically identifying optimal imaging and offering diagnostic insights in real-time, without the need for internet or cloud connectivity.

Exo secured clearance from the FDA for four AI indications this year, increasing the total to nine clearances.

With the introduction of SweepAI, Exo Iris now features automated AI-based indicators for detection of acute decompensated heart failure, congestive heart failure, volume of stroke and heart rate and assess left ventricular wall hypertrophy.

Exo artificial intelligence vice-president Dornoosh Zonoobi said: “What sets SweepAI apart is its seamless feedback in allowing you to navigate to the right views with minimal cognitive overload.

“With built-in auto-capture tools that monitor your scanning session, you don’t need to start over if a patient moves. Our AI simplifies the process, ensuring accurate, dependable results every time.”

The release of SweepAI, along with additional imaging enhancements, signifies Exo's third major update in less than 12 months.

Furthermore, the company is expanding its offerings with the introduction of Exo U, the first on-device education platform aimed at mastering ultrasound techniques.

Exo U provides quick and engaging lessons, akin to 'TikTok for POCUS', directly within the app, simplifying the learning process for ultrasound procedures from probe placement to anatomy recognition.

The company has also unveiled new software upgrades and features for the Exo Iris device and the Exo Works platform.

These enhancements include auto-colour, auto-Doppler, auto-eFAST, an OB measurements package, and more.